Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus

被引:89
作者
Bakris, George L. [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; BLOOD-PRESSURE CONTROL; ALL-CAUSE MORTALITY; RENAL-FUNCTION; MULTIFACTORIAL INTERVENTION; FOLLOW-UP; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE;
D O I
10.4065/mcp.2010.0713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nephropathy Is a common microvascular complication among patients with type 2 diabetes mellitus and a major cause of kidney failure. It is characterized by albuminuria (>= 300 mg/d) and a reduced glomerular filtration rate and is often present at the time of diabetes diagnosis after the kidney has been exposed to chronic hyperglycemia during the prediabetic phase. A low glomerular filtration rate (< 60 mL/min/1.73 m(2)) is also an independent risk factor for cardiovascular events and death. Detection of diabetic nephropathy during its initial stages provides the opportunity for early therapeutic interventions to prevent or delay the onset of complications and improve outcomes. An intensive and multifactorial management approach is needed that targets all risk determinants simultaneously. The strategy should comprise lifestyle modifications (smoking cessation, weight loss, increased physical activity, and dietary changes) coupled with therapeutic achievement of blood glucose, blood pressure, and lipid goals that are evidence-based. Prescribing decisions should take into account demographic factors, level of kidney impairment, adverse effects, risk of hypoglycemia, tolerability, and effects on other risk factors and comorbidities. Regular and comprehensive follow-up assessments with appropriate adjustment of the therapeutic regimen to maintain risk factor control is a vital component of care, including referral to specialists, when required.
引用
收藏
页码:444 / 456
页数:13
相关论文
共 130 条
  • [1] Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
    Adler, AI
    Stratton, IM
    Neil, HAW
    Yudkin, JS
    Matthews, DR
    Cull, CA
    Wright, AD
    Turner, RC
    Holman, RR
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258): : 412 - 419
  • [2] Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts
    Afshinnia, Farsad
    Wilt, Timothy J.
    Duval, Sue
    Esmaeili, Abbas
    Ibrahim, Hassan N.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (04) : 1173 - 1183
  • [3] American Diabetes Association, 2010, DIABETES CARE, V33, pS11, DOI DOI 10.2337/dc10-S011
  • [4] [Anonymous], ATL CHRON KIDN DIS E
  • [5] [Anonymous], STARL NAT TABL PRES
  • [6] [Anonymous], NEW ENGL J MED
  • [7] [Anonymous], AV ROS MAL TABL PRES
  • [8] [Anonymous], PREC AC TABL PACK IN
  • [9] [Anonymous], 2009, Glucophage (metformin hydrochloride) and Glucophage XR (extended-release) prescribing information
  • [10] [Anonymous], 2010, BR J DIABETES VASC D, DOI DOI 10.1177/1474651409357035